You are here

Hamish Ryder

Director of Therapeutic Discovery Laboratories

Hamish has directed drug discovery at CRUK-TDL, and it's predecessor CRT-DL, since 2008. He has led the successful transition of our translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage. Prior to joining CRT-DL he held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. Hamish has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer. He has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). Hamish obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.